



Universiteit
Leiden
The Netherlands

Minor histocompatibility antigen specific cytotoxic and regulatory immune responses in health and disease

Dierselhuis, M.P.

Citation

Dierselhuis, M. P. (2015, January 20). *Minor histocompatibility antigen specific cytotoxic and regulatory immune responses in health and disease*. Retrieved from <https://hdl.handle.net/1887/31592>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/31592>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/31592> holds various files of this Leiden University dissertation.

Author: Dierselhuis, Miranda Pauline

Title: Minor histocompatibility antigen specific cytotoxic and regulatory immune responses in health and disease

Issue Date: 2015-01-20



CHAPTER I

Introduction

1. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

In 1957 the first human bone marrow transplantation for the treatment of a hematological malignancy was performed^{1, 2}. The results of the first series of bone marrow transplantation were very poor. This was improved by the introduction of matching of the patient and its donor for the Human Leukocyte Antigen (HLA)³⁻⁶, better pre-transplant conditioning and immunosuppression⁷⁻¹⁰. To date many patients are transplanted for various hematological malignancies¹¹, some solid tumors¹², hematological or immunological deficits¹³⁻¹⁵ and other non-malignant diseases, like metabolic disorders^{16, 17}. The number of performed transplantations increases every year and transplantation indication and transplant source are changing.

Although the results of transplantation improved enormously over the years, severe complications after hematopoietic stem cell transplantation (HSCT) including Graft versus Host Disease (GvHD)^{18, 19}, infections and transplant related toxicity still occur. Furthermore a significant number of patients experience relapse after transplantation for hematological malignancies²⁰. The curative effect of HSCT in hematological malignancies and solid tumors, needing high dose chemotherapy and/or lethal irradiation, is partially due to graft versus leukemia or graft versus tumor responses^{21, 22}. These responses can be enhanced by donor lymphocyte infusion (DLI)²³⁻²⁵, which will be further discussed in paragraph 2.1.

1.1 HEMATOPOIETIC STEM CELL TRANSPLANTATION GRAFT SOURCE

Depending of several factors like underlying disease, patient age, and transplant availability, patients receive either a bone marrow transplantation (BMT), peripheral blood stem cell transplantation (PBSCT) or umbilical cord blood transplantation (UCBT). The use of BMT has decreased over the years. In the most recent survey of the European Group for Blood and Marrow Transplantation (EBMT) 23% of hematopoietic transplants were BMT and 72% of patients received a PBSCT^{10, 26}. BMT was merely performed in patients with non-malignant diseases, especially in HLA-identical sibling transplantations and pediatric transplantations.

For BMT, cells are harvested from the donors iliac crest under local or general anesthesia, whereas for PBSCT hematopoietic stem cells are derived from peripheral blood in which the release of stem cells from the bone marrow has been increased by treatment of the donor with granulocyte colony stimulating factor (G-CSF)²⁷. This makes the latter procedure much more donor friendly. Depending of the patient's underlying disease, donor characteristics and local hospital protocols the either way obtained stem cell product is infused into the patient with or without T cell depletion²⁸. In the last two decades umbilical cord blood (UCB) as stem cell source is used more frequently²⁹⁻³¹. UCB is harvested from the placenta directly after birth, therewith

being the most donor friendly procedure. Cord blood in general is less antigen experienced than adult blood^{32, 33}. Therefore HLA matching is not as stringent as for other transplant sources³⁴, nevertheless still important^{35, 36}. Since the number of nucleated cells derived from cord blood is limited, UCBT was initially performed in pediatric patients only^{37, 38}. More recently double cord blood transplantation with good clinical results is performed in adults as well^{31, 39-41}. Since the many benefits of umbilical cord blood compared to bone marrow or peripheral blood stem cells, like lower incidence of Graft versus Host disease, fast availability and less stringent HLA-matching, it is believed that the use of UCBT will only increase in the coming years⁴².

2. MINOR HISTOCOMPATIBILITY ANTIGENS

Minor Histocompatibility (H) antigens were discovered shortly after the unraveling of the human leukocyte antigen (HLA)^{43, 44}. As mentioned above, matching for HLA, as observed in HLA-identical (sibling) and HLA-matched (unrelated) transplantations, increased survival and reduced morbidity enormously. Nevertheless even in HLA-identical transplantation adverse effects like GvHD and graft rejection occur^{18, 19, 43-45}. In GvHD, immune responses of the graft against host tissue result in severe damage of the skin, intestine and/or liver⁴⁵. This leads to severe morbidity and mortality, in which minor H antigens play an important role. The first described and still one of the most studied antigen, HY, is derived from the Y-chromosome and is involved in gender mismatched transplantation^{43, 44, 46, 47}.

Since the molecular identification of minor H antigens it has become clear that these antigens are polymorphic self-proteins presented in the context of HLA class I or HLA class II molecules⁴⁸⁻⁵⁰. To date the identification of new minor H antigens is quickly increasing⁵¹⁻⁵⁵. By now 24 autosomally encoded and 12 Y chromosome encoded relevant minor H antigens have been described (table 1 and 2). Minor H antigens can be broadly expressed on different cell types or are restricted to the hematopoietic system. Some of the hematopoietic restricted minor H antigens are expressed at tumor cells as well⁵⁶. These different expression patterns, broad versus restricted, can lead to both beneficial and adverse effects after HSCT^{43, 44, 57-59}. Hematopoietic restricted minor H antigen mismatches between a HLA-identical patient and donor have important anti-tumor or anti-leukemia (GvT or GvL) effects⁶⁰⁻⁶³. Whereas mismatches in broadly expressed antigens can lead to GvT or GvL responses⁵⁹, but can especially lead to severe GvHD^{57, 64, 65}.

2.1 MINOR H ANTIGENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

It is known that minor H antigens have both positive and negative effects after HSCT.

Table 1. Autosomally encoded minor H antigens

Minor H antigen	Restriction molecule	Tissue distribution	Ref
HA-1/A2	HLA-A*0201	Restricted: hematopoietic/solid tumor cells	50
HA-1/B60	HLA-B60	Restricted: hematopoietic cells	66
HA-2	HLA-A2	Restricted: hematopoietic cells	49
HA-3	HLA-A1	Broad	67
HA-8	HLA-A2	Broad	68
HB-1	HLA-B44	Restricted: hematopoietic cells	69
ACC-1	HLA-A24	Restricted: hematopoietic/solid tumor cells	70
ACC-2	HLA-B44	Restricted: hematopoietic/solid tumor cells	70
UGT2B17/A29	HLA-A29	Restricted: hematopoietic cells	71
UGT2B17/B44	HLA-B44	Restricted: hematopoietic cells	71
LRH-1	HLA-B7	Restricted: hematopoietic/solid tumor cells	72
SP110/ HwA9	HLA-A3	Restricted: hematopoietic cells	73
PANE1/ HwA10	HLA-A3	Restricted: hematopoietic cells	74
C19Orf48/ HwA11	HLA-A2	Restricted: solid tumor cells	75
LB-ECGF-1	HLA-B7	Restricted: solid tumor cells	76
CTSH/A31	HLA-A31	Restricted: hematopoietic cells	77
CTSH/A33	HLA-A33	Restricted: hematopoietic cells	77
LB-ADIR	HLA-A2	Restricted: hematopoietic/solid tumor cells	78
ACC-6	HLA-B44	Broad	79
CD19	HLA-DQA1*05/B1*02	Restricted: hematopoietic/solid tumor cells	80
UTA2-1	HLA-A2	Restricted: hematopoietic cells	81
ZAPHIR	HLA-B7	Restricted: solid tumor cells	82
LB-SWAP70-1Q	HLA-B*40:01	Restricted: hematopoietic cells	83
UTDP4-1	HLA-DP4	Restricted: hematopoietic cells	55

Table 2. HY encoded minor H antigens

Minor H antigen	Restriction molecule	Gene	Tissue distribution	Ref
A1/HY	HLA-A*0101	DFFRY	Broad	84, 85
A2/HY	HLA-A*0201	SMCY	Broad	86
A24/HY	HLA-A*2402	UTY	Broad	87
A33/HY	HLA-A*3303	TMSB4Y	Broad	88
B7/HY	HLA-B7	SMCY	Broad	46
B8/HY	HLA-B8	UTY	Restricted: hematopoietic cells	89
B52/HY	HLA-B*5201	RPS4Y	Restricted: hematopoietic/ solid tumor cells	90
B60/HY	HLA-B60	SMCY	Broad	91
DQ5/HY	HLA-DQ5	DBY	Broad	92
DRB1*1501/HY	HLA-DRB1*1501	DBY	Broad	93
DRB3*0301/HY	HLA-DRB3*0301	RPS4Y	Broad	94
DRB1*07:01HY	HLA-DR7	RPS4Y	Broad	95

The positive effects are leading in adoptive immunotherapy protocols. The mutual aim of these studies is to enhance GvL responses without the induction of GvHD. Before it was possible to specifically target minor H antigen specific responses, patients with severe hematological malignancies received donor lymphocyte infusion (DLI) to enhance the GvL effect after HSCT. Since these procedures were performed after HLA-identical sibling transplantation it was reasoned that minor H antigen mismatches were involved in the good clinical response of these patients^{23, 96}. The anti-leukemic response was later found to be indeed associated with hematopoietic restricted minor H antigen mismatches^{60, 97}. The drawback of these therapies is the increased risk of GvHD. Although there is evidence that the presence of GvHD might be needed or can be a surrogate marker for a good GvL response⁶³. Nevertheless DLI is less popular as it was a decade ago, because of the increased risk of GvHD and more importantly the current use of new drugs like monoclonal antibodies, which specifically target malignant cells²⁵.

In the meantime minor H antigen specific targeted immunotherapies after HSCT are under study. Clinical trials (EudraCT number 2012-002435-28 and 2012-002879-34) have recently started in which patients are vaccinated with hematopoietic restricted minor H antigenic peptides in order to enhance the GvL response⁹⁸⁻¹⁰⁰. Another method to induce minor H antigen specific responses is to perform transfers of minor H antigenic specific T cell receptors to generate hematopoietic restricted minor H antigen specific T cells. Clinical implementation of transfusion of these generated antigen specific T cells is being prepared¹⁰¹⁻¹⁰⁵ (EudraCT number 2007-004334-16 and 2010-02462520).

2.2 MINOR H ANTIGENS IN SOLID ORGAN TRANSPLANTATION

Whereas the clinical relevance of minor H antigens is well documented in HSCT^{57, 106, 107}, information on their impact in solid organ transplantation is scarce¹⁰⁸. Similar to HSCT HLA matching is important, since rejection is much more common in HLA partially-matched or fully-mismatched donor-recipient combinations. However, rejection of renal transplants still occurs in HLA-identical sibling pairs in whom 10-year survival has hovered at 68-70% in the most recent multi-center analyses^{109, 110}. It remains questionable whether minor H antigens play a role in solid organ transplantation. The impact of minor H antigen mismatches can be studied best in HLA-identical sibling transplantation. These studies, however, are hampered by the fairly low number of solid organ familial transplants and basically restrict itself to sib-sib renal transplantation. Nevertheless in recent years a number of studies have been executed in order to identify the role of minor H antigens in different settings of renal transplantation with conflicting results. The studies include mainly the effect of gender mismatches¹¹¹⁻¹¹⁴,

and some of a limited number of autosomally encoded minor H antigens both on acute and chronic rejection^{115, 116}. Table 3 summarizes studies wherein the role of minor H antigens in renal transplantation is well investigated.

Table 3. Overview of literature describing clinical associations regarding minor H antigen mismatches in renal transplantation

Year	Minor H antigen	Important findings	Reference
1978	A2/HY	Reduced graft survival of male organs in female HLA-A2 recipients	117
1981	A2/HY	HY cytotoxicity in acute rejection in HLA-identical sibling transplantation	118
1994	HY	No effect of HY in completely HLA matched living donor transplantation	119
2004	A2/HA-1	HA-1 cytotoxic and regulator T cells are found in tolerant kidney transplantation patients	120
2007	A2/HA-1	HA-1 mismatch associated with chronic allograft nephropathy	115
2007	HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, HwA9, UGT2B17 and HY	Possibility to reduce immunosuppression despite minor H antigen mismatches	121
2008	HY	Acute and chronic rejection associated with male grafts in female recipients	111
2008	HY	De novo HY-antibody formation associated with acute rejection	112
2008	HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1 and UGT2B17	Minor H antigen mismatches had no significant effect on death-censored 5-year graft survival	116
2009	HY	Acute, but not chronic rejection is associated with male grafts in female recipients	113
2012	HY	Less rejection of male donor kidneys in male recipients	114
2013	HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, HwA9, HwA10, HwA11, UGT2B17, LRH-1, LB-ECGF-1, CTSH, LB-ADIR, CD31 and HY	No effect of any minor in HLA-identical sibling transplantation	122

2.3 MINOR H ANTIGENS IN PREGNANCY

Pregnancy is considered to be the best experiment of nature to study transplantation. Although the fetus is haplo-identical to the mother, in general pregnancy goes without major (immunological) complications. This is mainly the result of the separate circulation of the mother and the fetus. Nevertheless this barrier between mother and child is not 100% secure. Still cells flow from mother to child and vice versa. This cell flow in mutual direction can lead to both cytotoxic and tolerogenic minor H antigen specific responses, which can be found for decades after pregnancy¹²³⁻¹²⁸. On the

one hand tolerogenic responses might play a role in the normal maintenance of pregnancy since in and around the uterus a tolerogenic environment is created¹²⁹⁻¹³². On the other hand, minor H antigen HY specific cytotoxic responses might play a role in secondary miscarriages after a first born boy¹³³. The clinical consequences of the presence of these responses further in life are difficult to predict. Probably they are of non-importance to women themselves. Nevertheless these immune responses become interesting when these women become HSCT donors¹³⁴.

3. CHIMERISM

Chimerism is retrieved from the Greek mythological figure Chimaera; a monster consisting partly of a lion, a goat and a dragon or a snake. Today chimerism is defined as the long term persistence of genetically different material within one individual¹³⁵. Transplantation of a solid organ or the hematopoietic system leads to macrochimerism. Smaller quantities of chimeric cells are referred to as microchimerism. This can be detected after blood transfusion^{136, 137} or after the physiological exchange of cells between mother and fetus during pregnancy^{135, 138-140}.

3.1 MICROCHIMERISM AFTER PREGNANCY

By now it is generally accepted that fetal cells travel to the mother during pregnancy^{135, 141}. Some of these cells have a stem cell like phenotype, which can remain in women for many years after full term pregnancy, resulting in fetal microchimerism (FMc)^{138, 139}. Cells do not only travel from child to mother, but from mother to child as well¹⁴². These cells can reside in the offspring for decades and is referred to as maternal microchimerism (MMc)¹³⁵. There is evidence that MMc might be replaced by FMc when girls grow up and become pregnant themselves¹⁴⁰. FMc is frequently studied by the detection of (fragments of) the Y-chromosome, resulting from pregnancies of a boy. Strikingly, male microchimerism can be found in nulliparous women as well. This has been shown in peripheral blood and tissue analyses¹⁴³⁻¹⁴⁵. Therefore not only maternal cells but microchimeric cells of other sources present in the mother can travel to the child as well¹³⁵. These cells can be derived from either previous male pregnancies of the nulliparous women's mother or from microchimeric cells already present in the mother from other sources. This phenomenon is referred to as transmaternal cell trafficking. With transmaternal cell trafficking male microchimerism in women with older brothers can be explained. Possible sources of male microchimerism in nulliparous women without older brothers are vanished male twins¹⁴⁶ or (un)known miscarriages of male fetuses¹⁴⁷⁻¹⁴⁹. Even male leukocytes present in semen may enter the female's circulation^{150, 151}.

3.2 CLINICAL CONSEQUENCES OF MICROCHIMERISM AND SUBSEQUENT IMMUNIZATION

The influence of FMc has merely been studied in the context of auto-immune diseases^{141, 152-155} and cancer¹⁵⁶⁻¹⁵⁸. Conflicting results have been published regarding this subject, describing either no association or a positive association between the presence of microchimerism and the incidence of auto-immune diseases or cancer. It is unknown which role microchimeric cells play in the pathogenesis of these diseases. Microchimeric cells are often found in autoreactive tissue. It remains questionable whether the presence of these cells are the cause or the consequence of auto-immunity. It is unknown whether microchimeric cells react against host tissue resulting in tissue damage or that the host reacts against the microchimeric cells, leading to inflammation and auto-immune reactivity¹⁵⁹. Furthermore there is evidence that FMc might play a role in regeneration of damaged tissue¹⁶⁰.

Immune responses after transplantation are possibly associated with chimerism. A beneficial effect of microchimerism has been described with established microchimerism and alloreactive Treg in the setting of solid organ transplantation¹⁶¹⁻¹⁶³. Until now the influence of the presence of microchimerism in a HSCT donor or recipient on outcome of the transplant is unknown.

4. THE HUMAN T CELL REPERTOIRE

It is generally accepted that the T cell repertoire is almost naïve at birth and is educated throughout life. Education of T cells starts in the thymus by rearrangement of the T cell receptor (TCR) and by positive and negative selection¹⁶⁴⁻¹⁶⁶. The specificity of the TCR is determined by the alpha and beta chain. During thymic selection 55 different alpha chains can be combined with 73 different beta chains. Together with the junction area (N-region) this combination leads to a variety of TCRs. To prevent auto-immunity only TCRs with intermediate affinity to self-peptide presented in host MHC will survive, referred to as positive selection¹⁶⁷. The thymocytes will further develop to become either CD4^{pos} or CD8^{pos} T cells. When matured, the T cells leave the thymus naïve. Although they have a specific TCR, which can only recognize a limited number of antigens, these T cells are not antigen specific yet. Only upon antigen recognition in combination with specific co-stimulation they will become mature antigen specific T cells. The many different TCRs enable T cells to make adequate immune responses against many different antigens. This results in a broad T cell repertoire. In combination with different co-stimulatory molecules CD4^{pos} and CD8^{pos} T cells have distinct functions. CD8^{pos} cytotoxic or killer T cells recognize the antigen in the context of HLA class I molecules on the surface of antigen presenting cells (APC) like dendritic cells (DC), monocytes and B cells. With or without the help of CD4^{pos} T cells they

play an important role in antigen specific immune responses. A subclass of T cells, namely regulatory T cells (Treg), keep the immune system in balance and minimize auto-immunity¹⁶⁸. Natural Treg are merely CD4^{pos}CD25^{high}Foxp3^{pos}. In general these T cells do not act in an antigen specific manner and maintain tolerance against auto-antigens¹⁶⁹. CD8^{pos} Treg seem to regulate in a more antigen specific manner^{170, 171}. Until now the identification of specific regulatory markers on CD8^{pos} Treg has been difficult. The few human studies describing CD8^{pos} antigen specific Treg describe different markers, like Foxp3, CTLA-4, CD40L, LAG-3, CD127, TGF-beta^{120, 171-173}.

4.1 MINOR H ANTIGEN SPECIFIC T CELL REPERTOIRE

As described in paragraph 2, minor H antigens are presented in MHC class I or MHC class II molecules. In general CD4^{pos} T helper cells recognize antigens presented in class II molecule and CD8^{pos} cytotoxic T cells, recognize antigens presented in the HLA class I molecule. Accordingly different CD4 and CD8 mediated minor H antigen specific responses have been described^{49, 94, 174, 175}. Most of the studied minor H antigen specific responses in transplantation are CD8^{pos} T cell mediated responses. This has several reasons. Firstly, the first described minor H antigens were CD8^{pos} and played an important role in antigen specific responses after transplantation. HLA-A2 restricted HY specific responses are important in GvHD^{44, 47} and HLA-A2 restricted HA-1 specific responses play an important role in GvL¹⁷⁶. Secondly, it is technically easier to study CD8^{pos} T cells; tetramer availability is merely HLA class I restricted and in vitro culturing and functional read-out systems have been further developed for CD8 mediated responses.

Apart from cytotoxic responses, tolerogenic responses against minor H antigens have been studied. Years after BMT¹⁷⁷ and renal transplantation¹²⁰ minor H antigen specific regulation has been described. Also after normal pregnancy¹²⁷ these responses are present in many women. It seems that minor H antigen specific CD8^{pos} Treg express CTLA-4 and TGF-beta and may regulate in an IL-10 dependent manner^{120, 127}.

As described above antigen specificity of the T cell is determined by its TCR. But within one individual and within the population the same antigen can be recognized by different TCRs leading to similar immune responses. Nevertheless some antigens are recognized by a limited number of TCRs. This has been described in relation to bacterial or viral antigens and in autoimmunity¹⁷⁸⁻¹⁸⁰. Strikingly, it seems that recognition of the minor H antigen HA-1 is restricted to a single TCR Vbeta chain^{181, 182}. HA-1 antigen specific T cells have been isolated by tetramer selection or clonal expansion from unrelated individuals. All the retrieved T cell clones expressed the TCR Vbeta TRBV7-9. Since HA-1 is a favorite target for antigen specific immunotherapy this finding has led to adoptive immunotherapy protocols in which the TCR is transferred¹⁰¹⁻¹⁰⁵.

Although good pre-clinical results have been made with TCR adoptive transfer studies it is not known whether HA-1 specific Treg also share this TRBV7-9. If so, infusion of HA-1 specific T cells might lead to adverse effects, meaning increasing the chance to relapse, instead of reducing this chance.

5. AIM OF THIS THESIS

In this thesis minor H antigen specific cytotoxic and regulatory immune responses are studied in health and disease. In the first three chapters several aspects of cell exchange and transmaternal cell trafficking between mother and child during pregnancy are investigated. It is questioned whether these responses influence transplantation outcome.

In chapter 2 the presence of minor H antigen specific cytotoxic T cells against non-maternal antigens in cord blood is described. It is generally believed that the immune system and therefore also cord blood is naïve and antigen inexperienced at birth. Before it has been described that already in cord blood minor H antigen specific T cells against non-inherited maternal antigens are present¹²⁶. In this chapter we investigated whether transmaternal cell trafficking leads to microchimerism in cord blood. Furthermore we questioned if these few non-maternal cells traveling to a new fetus can result in minor H antigen specific responses.

In chapter 3 possible consequences of this transmaternal cell trafficking in HSCT is explored. Taking birth order into account in HLA-identical sibling transplantation leads to better transplantation outcome when the donor is transplanted with its younger sibling^{183, 184}. Due to transmaternal cell trafficking the younger sibling might have come into contact with non-shared antigens of his older sibling in a tolerogenic environment during pregnancy¹⁸⁵. We questioned whether it is possible to relate this birth order effect to minor H antigen mismatches. This was investigated in an unique international collaborative study, in which we analyzed a group of 311 HLA-identical sibling transplantations.

As described above, after pregnancy microchimerism and minor H antigen specific cytotoxic and regulatory responses can be present. In chapter 4 we studied whether there is a correlation between the detectable presence of microchimerism in peripheral blood and minor H antigen specific regulatory responses. To address this question a cohort of women from whom detailed obstetric and family history could be collected, was studied. As a proof of principal the minor H antigen HY was used. In all these women male microchimerism in different leukocyte subsets was determined. Both class I and class II HY specific regulation was subsequently tested.

These first chapters study minor H antigens in relation to or in the context of HSCT.

In chapter 5 minor H antigen responses are studied in HLA-identical sibling renal transplantation. With a large international multicenter study we studied the effect of 15 autosomally encoded minor H antigens and the HY antigen on rejection after renal transplantation.

In the last chapter we studied the T cell receptor of HA-1 specific T cells in more detail. HA-1 specific TCR-transferred T cells are currently under study for clinical application. Therefore we questioned whether the formerly described restricted TCR Vbeta usage of HA-1 specific CTL^{181, 182} is also applicable for HA-1 specific Treg which is crucial information for the clinical application of HA-1 TCR transferred T cells.

IN CONCLUSION, this thesis emphasizes the presence of minor H antigen specific immune responses directly after birth, which will be present throughout life. The presence of minor H antigen mismatched microchimeric cells obtained through pregnancy from a mother or a child play a crucial role in this. Subsequent immunization against minor H antigens can lead to both cytotoxic and tolerogenic responses. Furthermore HA-1 specific T cells can share the same TCR Vbeta, yet being functionally different. The here performed studies enhances our understanding of immune reactions after HSCT and if applicable after renal transplantation, especially regarding the birth order effect and the assumed less favorable role of women as transplant donors.

REFERENCE LIST

1. Thomas ED, Lochte HL, Jr., Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. *N Engl J Med* 1957;257(11):491-496.
2. Thomas ED, Lochte HL, Jr., Cannon JH, Sahler OD, Ferrebee JW. Supralethal whole body irradiation and isologous marrow transplantation in man. *J Clin Invest* 1959;38:1709-1716.
3. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. *Lancet* 1968;2(7583):1366-1369.
4. Thomas E, Storb R, Clift RA et al. Bone-marrow transplantation. *N Engl J Med* 1975;292(16):832-902.
5. Petersdorf EW, Gooley TA, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. *Blood* 1998;92(10):3515-3520.
6. Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood* 2007;110(13):4576-4583.
7. Gluckman E, Horowitz MM, Champlin RE et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. *Blood* 1992;79(1):269-275.
8. Lowsky R, Takahashi T, Liu YP et al. Protective conditioning for acute graft-versus-host disease. *N Engl J Med* 2005;353(13):1321-1331.
9. Shimoni A, Nagler A. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. *Best Pract Res Clin Haematol* 2011;24(3):369-379.
10. Baldomero H, Gratwohl M, Gratwohl A et al. The EBMT activity survey 2009: trends over the past 5 years. *Bone Marrow Transplant* 2011;46(4):485-501.
11. Copelan EA. Hematopoietic stem-cell transplantation. *N Engl J Med* 2006;354(17):1813-1826.
12. Barrett D, Fish JD, Grupp SA. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. *Pediatr Clin North Am* 2010;57(1):47-66.
13. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. *Bone Marrow Transplant* 2008;42 Suppl 1:S49-S52.
14. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. *Nature* 2005;435(7042):620-627.
15. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. *N Engl J Med* 1990;322(7):417-421.
16. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. *Curr Opin Neurol* 1999;12(2):167-176.
17. Staba SL, Escolar ML, Poe M et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. *N Engl J Med* 2004;350(19):1960-1969.
18. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. *J Clin Oncol* 2001;19(16):3685-3691.
19. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. *Nat Rev Immunol* 2012;12(6):443-458.
20. Shah NN, Borowitz MJ, Steinberg SM et al. Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant* 2014.
21. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. *N Engl J Med* 1979;300(19):1068-1073.
22. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. *Nat Rev Cancer* 2004;4(5):371-380.
23. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. *Blood* 1995;86(5):2041-2050.
24. Okas M, Gertow J, Uzunel M et al. Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation. *J Immunother* 2010;33(1):96-105.
25. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. *Cancer Treat Rev* 2010;36(7):528-538.

26. Passweg JR, Baldomero H, Peters C et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. *Bone Marrow Transplant* 2014.
27. Weaver CH, Buckner CD, Longin K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. *Blood* 1993;82(7):1981-1984.
28. Craddock C, Bardy P, Kreiter S et al. Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. *Br J Haematol* 2000;111(3):797-800.
29. Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. *Clin Immunol* 2008;127(3):286-297.
30. McKenna DH, Brunstein CG. Umbilical cord blood: current status and future directions. *Vox Sang* 2011;100(1):150-162.
31. Majhail NS, Brunstein CG, Wagner JE. Double umbilical cord blood transplantation. *Curr Opin Immunol* 2006;18(5):571-575.
32. Mold JE, Venkatasubrahmanyam S, Burt TD et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. *Science* 2010;330(6011):1695-1699.
33. Paloczi K. Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells. *Leukemia* 1999;13 Suppl 1:S87-S89.
34. Delaney M, Ballen KK. The role of HLA in umbilical cord blood transplantation. *Best Pract Res Clin Haematol* 2010;23(2):179-187.
35. Kamani N, Spellman S, Hurley CK et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. *Biol Blood Marrow Transplant* 2008;14(1):1-6.
36. Rubinstein P, Hillyer C. Histocompatibility and immunogenetics in cord blood transplantation. *Biol Res* 2010;43(3):339-345.
37. Gluckman E, Broxmeyer HA, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med* 1989;321(17):1174-1178.
38. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. *N Engl J Med* 1997;337(6):373-381.
39. Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cord blood transplants). *Hematology Am Soc Hematol Educ Program* 2004;354-371.
40. Laughlin MJ, Barker J, Bambach B et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. *N Engl J Med* 2001;344(24):1815-1822.
41. Sideri A, Neokleous N, Brunet DLG et al. An overview of the progress on double umbilical cord blood transplantation. *Haematologica* 2011;96(8):1213-1220.
42. Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, Rocha V. Milestones in umbilical cord blood transplantation. *Br J Haematol* 2011;154(4):441-447.
43. Goulmy E, Termijtellen A, Bradley BA, van Rood JJ. Alloimmunity to human H-Y. *Lancet* 1976;2(7996):1206.
44. Goulmy E, Termijtellen A, Bradley BA, van Rood JJ. Y-antigen killing by T cells of women is restricted by HLA. *Nature* 1977;266(5602):544-545.
45. Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. *Lancet* 2009;373(9674):1550-1561.
46. Wang W, Meadows LR, den Haan JM et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. *Science* 1995;269(5230):1588-1590.
47. Kim YH, Faaij CM, Van Halteren AG et al. In situ detection of HY-specific T cells in acute graft-versus-host disease-affected male skin after sex-mismatched stem cell transplantation. *Biol Blood Marrow Transplant* 2012;18(3):381-387.
48. van Els CA, D'Amaro J, Pool J et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. *Immunogenetics* 1992;35(3):161-165.
49. den Haan JM, Sherman NE, Blokland E et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. *Science* 1995;268(5216):1476-1480.
50. den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. *Science* 1998;279(5353):1054-1057.
51. de Rijke B, van Horssen-Zoetbrood A, Veenbergen S et al. Refinement of molecular approaches to improve the chance of identification of hematopoietic-restricted minor histocompatibility antigens. *J Immunol Methods* 2008;329(1-2):125-137.
52. van Bergen CA, Rutten CE, van der Meijden ED et al. High-throughput characterization of 10

- new minor histocompatibility antigens by whole genome association scanning. *Cancer Res* 2010;70(22):9073-9083.
53. Armistead PM, Liang S, Li H et al. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. *PLoS ONE* 2011;6(8):e23217.
 54. Stone B, Rieck M, Rawlings CA et al. Identification of novel HLA class II target epitopes for generation of donor-specific T regulatory cells. *Clin Immunol* 2012;145(2):153-160.
 55. Oostvogels R, Lokhorst HM, Minnema MC et al. Identification of minor histocompatibility antigens based on the 1000 Genomes Project. *Haematologica* 2014.
 56. de Bueger MM, Bakker A, van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. *J Immunol* 1992;149(5):1788-1794.
 57. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. *N Engl J Med* 1996;334(5):281-285.
 58. Falkenburg JH, van de Corp, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. *Exp Hematol* 2003;31(9):743-751.
 59. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. *Blood* 2004;103(1):347-352.
 60. Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. *Proc Natl Acad Sci U S A* 2003;100(5):2742-2747.
 61. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. *Curr Opin Immunol* 2005;17(2):202-210.
 62. Hambach L, Nijmeijer BA, Aghai Z et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. *Leukemia* 2006;20(2):371-374.
 63. Mutis T, Brand R, Gallardo D, van BA, Niederwieser D, Goulmy E. Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. *Leukemia* 2010;24(7):1388-1392.
 64. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. *Nat Med* 1999;5(7):839-842.
 65. Stern M, Brand R, de Witte T et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. *American Journal of Transplantation* 2008;8(10):2149-2157.
 66. Mommaas B, Kamp J, Drijfhout JW et al. Identification of a Novel HLA-B60-Restricted T Cell Epitope of the Minor Histocompatibility Antigen HA-1 Locus. *J Immunol* 2002;169(6):3131-3136.
 67. Spierings E, Brickner AG, Caldwell JA et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. *Blood* 2003;102(2):621-629.
 68. Qin L, Ding Y, Tahara H, Bromberg JS. Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft. *J Immunol* 2001;166(4):2385-2393.
 69. Dolstra H, Fredrix H, Maas F et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. *J Exp Med* 1999;189(2):301-308.
 70. Akatsuka Y, Nishida T, Kondo E et al. Identification of a Polymorphic Gene, BCL2A1, Encoding Two Novel Hematopoietic Lineage-specific Minor Histocompatibility Antigens. *J Exp Med* 2003;197(11):1489-1500.
 71. Terakura S, Murata M, Warren EH et al. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. *Transplantation* 2007;83(9):1242-1248.
 72. Rijke BC, Horssen-Zoetbrood A, Beekman JM et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. *Journal of Clinical Investigation* 2005;115(12):3506-3516.
 73. Warren EH, Vigneron NJ, Gavin MA et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. *Science* 2006;313(5792):1444-1447.
 74. Brickner AG, Evans AM, Mito JK et al. The PANE1 gene encodes a novel human minor his-

- tocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. *Blood* 2006;107(9):3779-3786.
75. Tykodi SS, Fujii N, Vigneron N et al. C19orf48 encodes a minor histocompatibility antigen recognized by CD8(+) Cytotoxic T cells from renal cell carcinoma patients. *Clinical Cancer Research* 2008;14(16):5260-5269.
 76. Slager EH, Honders MW, van der Meijden ED et al. Identification of the angiogenic endothelial cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. *Blood* 2006;107:4954-4960.
 77. Torikai H, Akatsuka Y, Miyazaki M et al. The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303. *Br J Haematol* 2006;134:406-410.
 78. van Bergen CA, Kester MG, Jedema I et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. *Blood* 2007;109(9):4089-4096.
 79. Kawase T, Akatsuka Y, Torikai H et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. *Blood* 2007;110(3):1055-1063.
 80. Spaapen RM, Lokhorst HM, van den Oudenalder K et al. Toward targeting B cell cancers with CD4(+) CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. *J Exp Med* 2008;205(12):2863-2U87.
 81. Oostvogels R, Minnema MC, van EM et al. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. *Leukemia* 2012.
 82. Broen K, Levenga H, Vos J et al. A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR. *PLoS ONE* 2011;6(6):e21699.
 83. Griffioen M, Honders MW, van der Meijden ED et al. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. *Haematologica* 2012;97(8):1196-1204.
 84. Pierce RA, Field ED, den Haan JM et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. *J Immunol* 1999;163(12):6360-6364.
 85. Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. *Blood* 2000;95(3):1100-1105.
 86. Meadows L, Wang W, den Haan JM et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. *Immunity* 1997;6(3):273-281.
 87. Mortensen BK, Rasmussen AH, Larsen ME et al. Identification of a novel UTY-encoded minor histocompatibility antigen. *Scand J Immunol* 2012;76(2):141-150.
 88. Torikai H, Akatsuka Y, Miyazaki M et al. A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. *J Immunol* 2004;173(11):7046-7054.
 89. Warren EH, Gavin MA, Simpson E et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. *J Immunol* 2000;164(5):2807-2814.
 90. Ivanov R, Aarts T, Hol S et al. Identification of a 40S ribosomal protein S4 - Derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response. *Clinical Cancer Research* 2005;11(5):1694-1703.
 91. Vogt MH, Goulmy E, Kloosterboer FM et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T- cell recognition. *Blood* 2000;96(9):3126-3132.
 92. Vogt MH, van den Muijsenberg J, Goulmy E et al. The DBY gene codes for an HLA-DQ5 restricted human male specific minor histocompatibility antigen involved in GvHD. *Blood* 2002;99(8):3027-3032.
 93. Zorn E, Miklos DB, Floyd BH et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. *J Exp Med* 2004;199(8):1133-1142.
 94. Spierings E, Vermeulen C, Vogt MH et al. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. *Lancet*

- 2003;362(9384):610-615.
95. Eljaafari A, Yuruker O, Ferrand C et al. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone. *J Immunol* 2013;190(1):184-194.
 96. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. *Bone Marrow Transplantation* 2008;41(5):483-493.
 97. Kloosterboer FM, Luxemburg-Heijs SAP, van Soest RA et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. *Leukemia* 2004;18(4):798-808.
 98. Mutis T, Ghoreschi K, Schrama E et al. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. *Biol Blood Marrow Transplant* 2002;8(8):412-419.
 99. Rice J, Buchan S, Dewchand H, Simpson E, Stevenson FK. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. *J Immunol* 2004;173(7):4492-4499.
 100. Li N, Matte-Martone C, Zheng H et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. *Blood* 2011;118(22):5965-5976.
 101. Heemskerk MH, Hoogeboom M, de Paus RA et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* 2003;102(10):3530-3540.
 102. Mommaas B, Van Halteren AG, Pool J et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. *Haematologica* 2005;90(10):1415-1421.
 103. Heemskerk MH, Griffioen M, Falkenburg JH. T-cell receptor gene transfer for treatment of leukemia. *Cytotherapy* 2008;10(2):108-115.
 104. van Loenen MM, de BR, Hagedoorn RS, van Egmond EH, Falkenburg JH, Heemskerk MH. Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies. *Haematologica* 2011;96(3):477-481.
 105. van Loenen MM, de BR, van LE et al. A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells. *Haematologica* 2014;99(4):759-768.
 106. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. *Hum Immunol* 2006;67(6):433-438.
 107. Dickinson AM, Wang XN, Sviland L et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. *Nat Med* 2002;8(4):410-414.
 108. Dierselhuys M, Goulmy E. The relevance of minor histocompatibility antigens in solid organ transplantation. *Current Opinion in Organ Transplantation* 2009;14(4):419-425.
 109. Cecka JM. The OPTN/UNOS renal transplant registry. *Clin Transpl* 2004;1-16.
 110. Gratwohl A, Doehler B, Stern M, Bucher C, Passweg J, Opelz G. Birth order and outcome after HLA-identical sibling donor transplantation. *Blood* 2009;114(27):5569-5570.
 111. Gratwohl A, Dohler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. *Lancet* 2008;372(9632):49-53.
 112. Tan JC, Wadia PP, Coram M et al. H-Y antibody development associates with acute rejection in female patients with male kidney transplants. *Transplantation* 2008;86(1):75-81.
 113. Kim SJ, Gill JS. H-Y incompatibility predicts short-term outcomes for kidney transplant recipients. *J Am Soc Nephrol* 2009;20(9):2025-2033.
 114. Tan JC, Kim JP, Chertow GM, Grumet FC, Desai M. Donor-recipient sex mismatch in kidney transplantation. *Gen Med* 2012;9(5):335-347.
 115. Krishnan NS, Higgins RM, Lam FT et al. HA-1 mismatch has significant effect in chronic allograft nephropathy in clinical renal transplantation. *Transplant Proc* 2007;39(5):1439-1445.
 116. Heinold A, Opelz G, Scherer S et al. Role of minor histocompatibility antigens in renal transplantation. *American Journal of Transplantation* 2008;8(1):95-102.
 117. Goulmy E, Bradley BA, Lansbergen Q, van Rood JJ. The importance of H-Y incompatibility in human organ transplantation. *Transplantation* 1978;25(6):315-319.
 118. Pfeffer PF, Sodal G, Thorsby E. HLA-restricted cell-mediated cytotoxicity directed against male specific (H-Y) antigen after acute rejection of an HLA-identical sibling kidney. *Scand J Urol Nephrol Suppl* 1981;64:72-78.

119. Ellison MD, Norman DJ, Breen TJ, Edwards EB, Davies DB, Daily OP. No Effect of H-y Minor Histocompatibility Antigen in Zero-Mismatched Living-Donor Renal-Transplants. *Transplantation* 1994;58(4):518-520.
120. Cai J, Lee J, Jankowska-Gan E et al. Minor H Antigen HA-1-specific Regulator and Effector CD8+ T Cells, and HA-1 Microchimerism, in Allograft Tolerance. *J Exp Med* 2004;199(7):1017-1023.
121. Gerrits JH, van de WJ, Postma S et al. Stable T-cell reactivity after successful tapering of azathioprine in HLA-identical living-related kidney transplant recipients despite minor histocompatibility antigen mismatches. *Nephrol Dial Transplant* 2007;22(2):353-361.
122. Dierselhuys MP, Spierings E, Drabbels J et al. Minor H antigen matches and mismatches are equally distributed among recipients with or without complications after HLA identical sibling renal transplantation. *Tissue Antigens* 2013;82(5):312-316.
123. James E, Chai JG, Dewchand H, Macchiarulo E, Dazzi F, Simpson E. Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. *Blood* 2003;102(1):388-393.
124. Verdijk RM, Kloosterman A, Pool J et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. *Blood* 2004;103:1961-1964.
125. Piper KP, McLarnon A, Arrazi J et al. Functional HY-specific CD8+ T cells are found in a high proportion of women following pregnancy with a male fetus. *Biol Reprod* 2007;76(1):96-101.
126. Mommaas B, Stegehuis-Kamp JA, Van Halteren AG et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. *Blood* 2004;105(4):1823-1827.
127. van Halteren AGS, Jankowska-Gan E, Joosten A et al. Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. *Blood* 2009;114(11):2263-2272.
128. Lissauer D, Piper K, Goodyear O, Kilby MD, Moss PA. Fetal-specific CD8+ cytotoxic T cell responses develop during normal human pregnancy and exhibit broad functional capacity. *J Immunol* 2012;189(2):1072-1080.
129. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. *Immunology* 2004;112(1):38-43.
130. Tilburgs T, Roelen DL, van der Mast BJ et al. Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. *J Immunol* 2008;180(8):5737-5745.
131. Scherjon S, Lashley L, van der Hoorn ML, Claas F. Fetus specific T cell modulation during fertilization, implantation and pregnancy. *Placenta* 2011.
132. Dimova T, Nagaeva O, Stenqvist AC et al. Maternal Foxp3 expressing CD4+ CD25+ and CD4+. *Am J Reprod Immunol* 2011;66 Suppl 1:44-56.
133. Christiansen OB, Steffensen R, Nielsen HS. Anti-HY responses in pregnancy disorders. *Am J Reprod Immunol* 2011;66 Suppl 1:93-100.
134. Loren AW, Bunin GR, Boudreau C et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2006;12(7):758-769.
135. Gammill HS, Nelson JL. Naturally acquired microchimerism. *International Journal of Developmental Biology* 2010;54(2-3):531-543.
136. Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. *Blood* 1999;93(9):3127-3139.
137. Utter GH, Owings JT, Lee TH et al. Microchimerism in transfused trauma patients is associated with diminished donor-specific lymphocyte response. *Journal of Trauma-Injury Infection and Critical Care* 2005;58(5):925-931.
138. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. *Proc Natl Acad Sci U S A* 1996;93(2):705-708.
139. O'Donoghue K, Chan J, de la FJ et al. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. *Lancet* 2004;364(9429):179-182.
140. Gammill HS, Guthrie KA, Aydelotte TM, Waldorf KMA, Nelson JL. Effect of parity on fetal and

- maternal microchimerism: interaction of grafts within a host? *Blood* 2010;116(15):2706-2712.
141. Bianchi DW. Fetomaternal cell traffic, pregnancy-associated progenitor cells, and autoimmune disease. *Best Practice & Research in Clinical Obstetrics & Gynaecology* 2004;18(6):959-975.
 142. Stevens AM, Hermes HM, Kiefer MM, Rutledge JC, Nelson JL. Chimeric maternal cells with tissue-specific antigen expression and morphology are common in infant tissues. *Pediatr Dev Pathol* 2009;12(5):337-346.
 143. Yan Z, Lambert NC, Guthrie KA et al. Male microchimerism in women without sons: Quantitative assessment and correlation with pregnancy history. *American Journal of Medicine* 2005;118(8):899-906.
 144. Koopmans M, Kremer H, I, Baelde HJ et al. Chimerism in kidneys, livers and hearts of normal women: implications for transplantation studies. *Am J Transplant* 2005;5(6):1495-1502.
 145. Guettier C, Sebagh M, Buard J et al. Male cell microchimerism in normal and diseased female livers from fetal life to adulthood. *Hepatology* 2005;42(1):35-43.
 146. de Bellefon LM, Heiman P, Kanaan SB et al. Cells from a vanished twin as a source of microchimerism 40 years later. *Chimerism* 2010;1(2):56-60.
 147. Ariga H, Ohto H, Busch MP et al. Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. *Transfusion* 2001;41(12):1524-1530.
 148. Sato T, Fujimori K, Sato A, Ohto H. Microchimerism after induced or spontaneous abortion. *Obstet Gynecol* 2008;112(3):593-597.
 149. Khosrotehrani K, Johnson KL, Lau J, Dupuy A, Cha DH, Bianchi DW. The influence of fetal loss on the presence of fetal cell microchimerism: a systematic review. *Arthritis Rheum* 2003;48(11):3237-3241.
 150. Moldenhauer LM, Diener KR, Thring DM, Brown MP, Hayball JD, Robertson SA. Cross-presentation of male seminal fluid antigens elicits T cell activation to initiate the female immune response to pregnancy. *J Immunol* 2009;182(12):8080-8093.
 151. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. *J Infect Dis* 1997;176(4):960-968.
 152. Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. *Blood* 1999;93(6):2033-2037.
 153. Sarkar K, Miller FW. Possible roles and determinants of microchimerism in autoimmune and other disorders. *Autoimmunity Reviews* 2004;3(6):454-463.
 154. Rak JM, Maestroni L, Balandraud N et al. Transfer of the shared epitope through microchimerism in women with rheumatoid arthritis. *Arthritis Rheum* 2009;60(1):73-80.
 155. Yan Z, Aydelotte T, Gadi VK, Guthrie KA, Nelson JL. Acquisition of the rheumatoid arthritis HLA shared epitope through microchimerism. *Arthritis Rheum* 2011;63(3):640-644.
 156. Gilmore GL, Haq B, Shaddock RK, Jasthy SL, Lister J. Fetal-maternal microchimerism in normal parous females and parous female cancer patients. *Exp Hematol* 2008;36(9):1073-1077.
 157. Cirello V, Perrino M, Colombo C et al. Fetal cell microchimerism in papillary thyroid cancer: studies in peripheral blood and tissues. *Int J Cancer* 2010;126(12):2874-2878.
 158. Gadi VK. Fetal microchimerism and cancer. *Cancer Letters* 2009;276(1):8-13.
 159. Lepez T, Vandewoestyne M, Deforce D. Fetal microchimeric cells in autoimmune thyroid diseases: harmful, beneficial or innocent for the thyroid gland? *Chimerism* 2013;4(4):111-118.
 160. Nijagal A, MacKenzie TC. Clinical implications of maternal-fetal cellular trafficking. *Semin Pediatr Surg* 2013;22(1):62-65.
 161. Ichinohe T, Uchiyama T, Shimazaki C et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. *Blood* 2004;104(12):3821-3828.
 162. Burlingham WJ, Grailer AP, Fechner JH, Jr. et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. *Transplantation* 1995;59(8):1147-1155.
 163. Alexander SI, Smith N, Hu M et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. *N Engl J Med* 2008;358(4):369-374.
 164. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. *Ann Rev Immunol* 2003;21:139-176.
 165. Huseby ES, Kappler JW, Marrack P. Thymic selection stifles TCR reactivity with the main chain structure of MHC and forces interactions with the peptide side chains. *Mol Immunol*

- 2008;45(3):599-606.
166. Gascoigne NR, Palmer E. Signaling in thymic selection. *Curr Opin Immunol* 2011;23(2):207-212.
 167. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. *Nature* 1999;402(6759):255-262.
 168. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? *Int Immunol* 2009;21(10):1105-1111.
 169. Allan SE, Broady R, Gregori S et al. CD4(+) T-regulatory cells: toward therapy for human diseases. *Immunological Reviews* 2008;223:391-421.
 170. Mjosberg J, Berg G, Ernerudh J, Ekerfelt C. CD4+ CD25+ regulatory T cells in human pregnancy: development of a Treg-MLC-ELISPOT suppression assay and indications of paternal specific Tregs. *Immunology* 2007;120(4):456-466.
 171. Joosten SA, van Meijgaarden KE, Savage ND et al. Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. *Proc Natl Acad Sci U S A* 2007;104(19):8029-8034.
 172. Suzuki M, Konya C, Goronzy JJ, Weyand CM. Inhibitory CD8+ T cells in autoimmune disease. *Hum Immunol* 2008;69(11):781-789.
 173. Mahic M, Henjum K, Yaqub S et al. Generation of highly suppressive adaptive CD8(+)/CD25(+)/FOXP3(+) regulatory T cells by continuous antigen stimulation. *Eur J Immunol* 2008;38(3):640-646.
 174. van Els CA, Zantvoort E, Jacobs N, Bakker A, van Rood JJ, Goulmy E. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules. *Bone Marrow Transplant* 1990;5(6):365-372.
 175. van der Harst D, Goulmy E, Falkenburg JH et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. *Blood* 1994;83(4):1060-1066.
 176. Kircher B, Wolf M, Stevanovic S et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. *J Immunother* 2004;27(2):156-160.
 177. de Bueger M, Bakker A, Goulmy E. Acquired tolerance for minor histocompatibility antigens after HLA identical bone marrow transplantation. *Int Immunol* 1992;4(1):53-57.
 178. Luo W, Ma L, Wen Q, Wang N, Zhou MQ, Wang XN. Analysis of the interindividual conservation of T cell receptor alpha- and beta-chain variable regions gene in the peripheral blood of patients with systemic lupus erythematosus. *Clin Exp Immunol* 2008;154(3):316-324.
 179. Bowerman NA, Falta MT, Mack DG et al. Identification of Multiple Public TCR Repertoires in Chronic Beryllium Disease. *J Immunol* 2014.
 180. Qiao SW, Christophersen A, Lundin KE, Sollid LM. Biased usage and preferred pairing of alpha- and beta-chains of TCRs specific for an immunodominant gluten epitope in coeliac disease. *Int Immunol* 2014;26(1):13-19.
 181. Goulmy E, Pool J, van den Elsen PJ. Interindividual conservation of T-cell receptor beta chain variable regions by minor histocompatibility antigen-specific HLA-A*0201- restricted cytotoxic T-cell clones. *Blood* 1995;85(9):2478-2481.
 182. Verdijk RM, Mutis T, Wilke M et al. Exclusive TCRVbeta chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping. *Hematol J* 2002;3(6):271-275.
 183. Bucher C, Stern M, Buser A et al. Role of primacy of birth in HLA-identical sibling transplantation. *Blood* 2007;110(1):468-469.
 184. Dobbelsstein C, Ahn KW, Haagenson M et al. Birth order and transplant outcome in HLA-identical sibling stem cell transplantation - an analysis on behalf of the Center for International Blood and Marrow Transplantation (CIBMTR). *Biol Blood Marrow Transplant* 2013.
 185. Mold JE, Michaelsson J, Burt TD et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. *Science* 2008;322(5907):1562-1565.

